Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now

Walgreens to settle Rite Aid investors' merger claims for $192 million

Published 10/19/2023, 11:24 AM
Updated 10/19/2023, 04:27 PM
© Reuters. FILE PHOTO: A sign advertises COVID-19 (coronavirus) vaccine shots at a Walgreens Pharmacy in Somerville, Massachusetts, U.S., August 14, 2023.     REUTERS/Brian Snyder/File Photo

(Reuters) -Walgreens Boots Alliance has agreed to pay $192.5 million to settle a class action lawsuit by investors in Rite Aid (NYSE:US90274J5618=UBSS) who accused Walgreens of misleading them in 2017 about scrutiny of the two drugstore chain operators' then-pending merger.

The deal filed in Pennsylvania federal court on Wednesday is subject to approval by District Judge Jennifer Wilson.

David Knotts, an attorney for the shareholders, said the case was "intensely fought." "We're very pleased with the result and look forward to the court's review," he said.

A spokesperson for Walgreens declined to comment.

The Rite Aid investors sued Walgreens and its executives over statements they made about the proposed merger between the two major U.S. pharmacy chains, which was first announced in 2015.

The lawsuit accuses Walgreens of downplaying scrutiny from U.S. antitrust regulators starting in October 2016.

Walgreens ultimately scrapped the takeover plan in June 2017 after failing to win approval from the Federal Trade Commission.

Walgreens, which operates stores under its own name as well as Boots stores in Britain and Duane Reade stores in the United States, instead bought around 42% of Rite Aid's existing stores that year for $4.38 billion.

The settlement with investors comes on the heels of Rite Aid filing for bankruptcy protection as it struggled with high debt and costs from opioid litigation.

Under the current proposed bankruptcy plan, the company's shares would be dissolved with no compensation to shareholders.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.